Skip to main content
Premium Trial:

Request an Annual Quote

Rules-Based Medicine to Collaborate with Charles River Labs

NEW YORK, May 13 - Charles River Laboratories International has signed an agreement to exclusively market and provide services for Rules-Based Medicine's Multi-Analyte Profiles (MAPS) for phenotypically characterizing laboratory research animals, the companies said today.

 

The MAP assay will "become our primary screening assay for viral antibody serology," said William Shek, senior technical director of Charles River's diagnostic and research services, in a statement.   The company will make reports of progress on these assays available to customers on its laboratory information management system

 

The MAP system includes 100 fluorescent microspheres dyed different colors, along with a bioassay, and a laser fluorescence detection system. On the beads are tests for plasma biomarkers including tissue-specific enzymes, hormones, cytokines, chemokines and acute-phase reactants. It is similar to the microsphere technology made by Luminex, of which Rules-Based Medicine is a spinoff.

 

The companies did not disclose the financial terms of the agreement. Charles River is based in Wilmington, Mass., and Rules-Based Medicine is based in Austin, Texas.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.